GO
| HSI1 | 24,498.95 | 0.00 | -- |
| HSCEI1 | 8,853.10 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2025-07-17 10:10:07 Nomura issued a research report expecting that CSPC PHARMA (01093.HK)'s 2Q25 revenue will hike 7.4% YoY to RMB7.8 billion, in line with market expectations. Finished drug sales are expected to decline by 9%, while revenue from business development (BD) will be approximately RMB1 billion, helping to drive revenue growth. The 2Q25 gross profit margin is projected to slightly drop by 0.7 ppts to 70%, on a mix of about 65% for finished drug sales and 100% for BD revenue. Therefore, Nomura kept rating at Buy for CSPC PHARMA, and cut its target price slightly from $10.22 to $10.09. The broker also lowered its full-year revenue forecast by 3.6%, but lifted its earnings forecast by 2.7% due to reduced sales expenses. ~ AASTOCKS Financial News Website: www.aastocks.com | |